Evidence map›Paper›PMID 41974931›Full record

ArticleVirchows Archiv : an international journal of pathology2026

First report of synchronous papillary, medullary, and thymic carcinomas in a patient carrying a germline heterozygous MUTYH mutation.

Luanxue Yu, Nan Song, Jiawei Ming, Yu Wang, Sofia Asioli, Zhenying Guo, Minghua Ge

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Luanxue Yu *School of Pharmacy, Hangzhou Normal University, Hangzhou, China.
Nan Song *Cancer Center, Department of Pathology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, China.
Jiawei MingSchool of Public Health, Hangzhou Medical College, Hangzhou, China.
Yu WangCancer Center, Department of Pathology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, China.
Sofia AsioliDepartment of Biomedical and Neuromotor Sciences (DIBINEM) , Alma Mater Studiorum - University of Bologna, IRCCS Istituto Delle Scienze Neurologiche Di Bologna, Via Altura No. 3, Bologna, Italy.
Zhenying GuoCancer Center, Department of Pathology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, China. guozy@zjcc.org.cn.ORCID http://orcid.org/0009-0001-8482-3121
Minghua GeOtolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China. geminghua@hmc.edu.cn.ORCID http://orcid.org/0000-0001-6726-6418

Funding

National Natural Science Foundation of China 81602348National Natural Science Foundation of China 82072577
6 · The paper itself

Abstract

MUTYH-associated polyposis (MAP) is an autosomal recessive tumor syndrome caused by biallelic mutations in the MUTYH gene, primarily associated with an increased risk of colorectal adenomas and carcinoma. However, the tumor spectrum in heterozygous MUTYH mutation carriers remains poorly defined. Here, we report the first case of a patient with a germline heterozygous MUTYH mutation who developed metachronous multiple primary tumors. The patient initially presented with a thyroid collision tumor (synchronous papillary thyroid carcinoma and medullary thyroid carcinoma) at age 55. Two years later, he was diagnosed with non-keratinizing squamous cell carcinoma of the thymus, accompanied by left cervical lymph node metastasis of papillary thyroid carcinoma (PTC). Subsequent next-generation sequencing of the lymph node metastasis revealed a novel heterozygous MUTYH frameshift mutation, c.848delT (p.M283Rfs*3), which was confirmed to be of germline origin by Sanger sequencing of the patient's normal thyroid tissue. This case expands the disease spectrum associated with heterozygous MUTYH carriers and enhances the understanding of the phenotypic heterogeneity of tumors in this population.

Indexed as

Cancer geneticsGermline heterozygous mutationMedullary thyroid carcinomaMUTYHPapillary thyroid carcinomaThymic carcinoma

Identifiers

PMID41974931

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.